<DOC>
	<DOCNO>NCT01958281</DOCNO>
	<brief_summary>This study evaluate safety , tolerability antiviral efficacy sofosbuvir ( SOF ) ribavirin ( RBV ) participant GT 1 3 ledipasvir ( LDV ) /SOF participant genotype 1 4 HCV infection chronic renal insufficiency ( impaired kidney function ) . Approximately 35 subject severe renal insufficiency ( dialysis ) enrol 3 cohort . - Cohort 1 ( GT 1 3 ) : 10 subject receive SOF 200 mg + RBV 200 mg daily 24 week . - Cohort 2 ( GT 1 3 ) : Following review safety , efficacy pharmacokinetics ( PK ) data post-treatment Week 4 Cohort 1 , 10 additional subject receive SOF 400 mg + RBV 200 mg daily 24 week . - Cohort 3 ( GT 1 4 ) : Following review safety available PK data Week 12 Cohort 2 , 15 additional subject receive LDV/SOF 90/400 mg daily 12 week .</brief_summary>
	<brief_title>Sofosbuvir Plus Ribavirin , Ledipasvir/Sofosbuvir Adults With HCV Infection Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Key Cohorts 1 2 : chronic genotype 1 3 HCV infection Cohort 3 : chronic genotype 1 4 HCV infection HCV RNA â‰¥ 10^4 IU/mL screen Screening lab within defined threshold Cirrhosis determination screen Key Females pregnant nursing male pregnant partner Prior null response PEG+RBV therapy Current prior history hepatic decompensation Infection hepatitis B virus ( HBV ) HIV History clinically significant illness ( include psychiatric cardiac ) medical disorder may interfere individual 's treatment and/or adherence protocol Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>